Ceryvyn Therapeutics
Short position
Ceryvyn Therapeutics (ASX:CYV) has 0.23% of its shares on issue reported as short positions as of 5 Oct 2026, or about 3,196,278 shares. Over the past 30 days that figure has fallen 0.05 percentage points, and over 7 days it has been broadly flat. Its highest recorded short interest was 0.97% in September 2026. CYV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Ceryvyn Therapeutics (CYV) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $1.0KM (source: ASX (Markit))vs $228.0KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- $330.4MM (source: ASX (Markit))vs −$251.1MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (basic)
- n/avs n/a (FY25)
- Rev YoY
- n/mFY
- EPS YoY
- n/aFY
- ASX (Markit)
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- 33,044,500.0%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $1.0KM (source: ASX (Markit)) | $228.0KM (source: ASX (Markit)) | $190.2KM (source: ASX (Markit)) | $161.2KM (source: ASX (Markit)) |
| NPAT | $330.4MM (source: ASX (Markit)) | −$251.1MM (source: ASX (Markit)) | −$336.1MM (source: ASX (Markit)) | −$211.9MM (source: ASX (Markit)) |
| Shares | n/a | 1.23B | 1.09B | 538.0M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D and Half Year Report for period 31 Dec 2025Half Year Results2 Mar 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Annual Report to shareholdersAnnual Report15 Sep 2025via asx_announcements
- Preliminary Final ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
Showing 10 of 20 reports